SMAD4 and gastric cancer: Combined immune checkpoint blockade (ICB) with anti-PD-L1 and anti-CTLA-4 or agonistic anti-4-1BB antibodies effectively treats ICB monotherapy-resistant SMAD4-deficient allografts, providing a rational basis for an ICB strategy to treat advanced SMAD4-deficient GC [38].